MedTrace Logo

Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects

NCT02651623 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2021-01-27

No results posted yet for this study

Summary

The purpose of this study is to demonstrate a lack of effect of sertraline on QTc intervals relative to time-matched placebo in healthy subjects

Conditions

  • Healthy

Interventions

DRUG

Sertraline

Multiple doses of sertraline for 14 days

DRUG

Moxifloxacin

A single dose of 400 mg Moxifloxacin

DRUG

Drug - Placebo

Placebo administered for 14 days

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02651623 on ClinicalTrials.gov